Financial insights of BRNS

MyFinsight

For the quarter ending 2026-03-31.

Income Statement	2026-03-31	2025-12-31	2025-09-30	2025-06-30
Total revenue-License	-	-	0	-
Total revenue	0	0*	0	-
Total revenue-License	0	-	-	-
Impairment of long-lived assets	0	-9,334*	4,667	-
Research and development	3,593	5,550*	5,390	7,953
Goodwill impairment	-	0*	-	-
General and administrative	2,528	17,007*	5,165	15,384
Total operating expenses	6,121	13,222*	15,222	23,337
Other operating income	46	253*	156	13
Loss from operations	-6,075	-12,969*	-15,066	-23,324
Interest income	350	465*	472	523
Interest expense	13	14*	13	12
Research and development incentives	149	-373*	240	1,342
Other income	39	-51*	-275	320
Total other income, net	525	27*	424	2,173
Loss before income tax	-5,550	-12,943*	-14,642	-21,151
Tax benefit	-16	-31*	-71	-25
Net loss	-5,534	-12,912*	-14,571	-21,126
Net loss attributable to noncontrolling interest	-3	-19*	-5	-2
Net loss attributable to barinthus biotherapeutics plc shareholders	-5,531	-12,893	-14,566	-21,124

Basic EPS	-0.14	-0.318	-0.36	-0.52
Diluted EPS	-0.14	-0.318	-0.36	-0.52
Basic Average Shares	40,848,893	40,577,015	40,661,118	40,343,521
Diluted Average Shares	40,848,893	40,577,015	40,661,118	40,343,521

Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.